Alira Health

Download our 2024 Global Biosimilars Report for an assessment of trends in the global biosimilar market, with an emphasis on market and competitive dynamics in the US and Europe: https://lnkd.in/gVzx7vTF Connect with the authors to discuss more about the report: Alexandra Wollersheim, Joris Pezzini, Christian Hughes, Nicole Clarke, PhD, MSM, and Alina Greimel.

What’s the biggest challenge you're facing in launching a medical device in Europe? If it’s navigating the complex regulatory environment, you’re not alone. Read our Interview with Mercè Guerra Albà: https://lnkd.in/eTGj-iYP She breaks down the regulatory challenges facing medtech companies in 2024 and shares strategies to ensure success. Learn how to stay ahead of evolving requirements and implement a winning approach.

Click right to discover insights on: ?? The rapid adoption of robotic-assisted knee and hip replacements. ?? Geographic growth opportunities in APAC markets like China, India, and Japan. ?? Cutting-edge technologies like VR and AR transforming orthopedic robotics. Dive deeper into these trends by downloading the full report: https://lnkd.in/e2VYbGbS

Read our article to learn how procurement and funding processes for radiopharmaceuticals differ across Europe, and what it means for hospitals and manufacturers: https://lnkd.in/gXpUgXz4 Radiopharmaceuticals are transforming oncology care, but their market access and procurement processes remain a challenge across Europe. Hospitals must choose between commercial products and in-house production, each with its own trade-offs in cost, convenience, and supply. Connect with the authors to discuss more about this topic: Irene Lizano, PhD, Sandra Walsh Capdevila, Ph.D., and Jessica Cruz Arrioja.

We’re grateful to everyone who attended our poster presentations at ISPOR Europe this year! Our team proudly presented 16 posters over three days, covering a wide range of therapeutic areas like oncology, cardiovascular, ophthalmology, and cell and gene. Each presentation reflected our commitment to advancing healthcare innovation and delivering actionable insights for patients, payers, and providers. A huge thank you to our talented presenters for sharing their expertise and to all the attendees for contributing to meaningful conversations. #ISPOREU

Discover how patient collaboration can transform market access strategies for rare disease treatments: https://lnkd.in/gz2Ti-HH In this interview, Annabel de Maria Bosch, Chief Patient Officer, and?Pepi Hurtado-Lopez, Managing Partner, Market Access & Pricing, share insights on co-creating strategies that ensure patients receive the treatments they need.

Meet us at ISPOR EU! We're ready to connect, collaborate, and dive deep into strategic consulting topics around access, evidence generation, pricing, and more to help drive your commercial success. Our team is presenting 16 posters during the event. Explore key insights into HEOR, real-world evidence, and market access, covering therapeutic areas like oncology, cardiovascular, ophthalmology, and cell and gene. Today we will present “Assessing the Value of Real-World Evidence for HTA Decision-Making,” which is a top 5% finalist for the ISPOR 2024 Research Presentation Awards. We look forward to seeing you there!

Meet Filippo Pendin, our Transaction Advisory expert in the CDMO biologics space. Filippo guides CDMOs, private equity firms, and biotech companies through the complex world of mergers, acquisitions, and strategic partnerships. He is one of the authors of the 2024 Biologics and Advanced Therapies Contract Manufacturing Report, which offers a comprehensive analysis of current industry trends and competitive dynamics across North America and Europe. Download it now: https://lnkd.in/gtRrqUAt Connect with Filippo to learn more about the latest transactions we supported.

Meet us at ACR Convergence 2024! We are at the FORWARD, The National Databank for Rheumatic Diseases, ready to discuss advances in lupus research. We’re also excited to present two posters, including one in collaboration with FORWARD on their lupus registry. Don’t miss this chance to connect with our expert delegates, Minjee Park and Jennifer Lannon.

Most radioligand therapies-focused companies are currently exploring the metastatic prostate cancer therapeutic area, where radioligand therapies have shown promising results. Click right to see the latest trends in this area. Download our paper, which provides an overview of the advent of radioligand therapies through the example of metastatic prostate cancer, highlighting clinical and development trends along with selected strategic considerations in key markets: https://lnkd.in/gxwDcp-T Connect with Florent Chouvy to learn more about the latest trends in nuclear medicine!